European patients with advanced EGFR mutation-positive non-small- cell lung cancer
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer ( EURTAC ) : a multicentre, open-label, randomised phase 3 trial .